View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

China Healthcare: Bi-Weekly: Affected By Geopolitical Headwinds

The China healthcare stocks under our coverage exhibited a mixed performance during 1-15 Sep 25. Internet healthcare majors like Ali Health and JD Health outperformed, with share prices rising 18.8% and 8.6% respectively, thanks to strong revenue growth prospects and potential policy support. Investors took profits on major biopharmas amid concerns over possible in-licensing restrictions from the US. The trend of innovation and globalisation among Chinese biopharmas remains strong, driven by rob...

Benyamin Mikael ... (+14)
  • Benyamin Mikael
  • Carol Dou Xiao Qin
  • Claire Wang Kelai
  • Damon Shen
  • Jieqi Liu
  • Jonathan Koh
  • Julia Pan Mengyao
  • Kasemsun Koonnara
  • Ming San Soong
  • Philip Wong
  • Sunny Chen
  • Tham Mun Hon
  • Willinoy Sitorus
  • Ziv Ang Sze Champ

Regional Morning Meeting Notes: Tuesday, September 09, 2025

Greater China Economics | Trade China’s export momentum softened in August as front-loaded US demand has faded, exposing the vulnerability of shipments to the US market. While the trade diversion supported flows to ASEAN and the EU, overall growth moderated. Imports also weakened amid subdued agricultural demand, despite firmer commodity-related inflows. Pro...

Eli Lilly & Co: 1 director

A director at Eli Lilly & Co sold 1,000 shares at 734.930USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Moody's Ratings assigns Aa3 rating to Eli Lilly's notes; stable outloo...

Moody's Ratings (Moody's) assigned a Aa3 rating to the new senior unsecured notes offering of Eli Lilly and Company ("Lilly"). There are no changes to Lilly's existing ratings including the Aa3 senior unsecured notes ratings and issuer rating, the (P)Aa3 senior unsecured shelf, the (P)Aa3 senior uns...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 16, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Novo - Upgrade to HOLD (PT DKK300, 8pgs)

With the orfo’ data being on the lower side of expectations, we upgrade to Hold as the narrative is likely to be dominated by the potential upside for Novo. However, we remain convinced that: 1) The obesity market is nowhere near as big as the market believes, 2) Ozempic no’s are far too high & 3) Margin forecasts need to fall. Cons’ Ozempic forecasts will take time to fall & we will likely need the IRA price in November to force consensus lower. Therefore, we see limited S-T downside to our DKK...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

HUTCHMED (China) (13 HK): 1H25: Divestment of non-core asset boosts ea...

1H25 revenue missed forecasts, but its robust earnings of US$455.6m beat market estimates. It targets lower oncology revenue of US$270m-350m on delays in milestone income and setbacks in Sovleplenib’s review progress, and expects domestic sales to recover from 2H25. Seeing smooth R&D progress and market approvals in major oncology products, HUTCHMED will likely see a new wave of market approvals to fuel growth in the years ahead. Maintain BUY with a lower target price of HK$32.50.

Bella Lu Yifei ... (+17)
  • Bella Lu Yifei
  • Benjaphol Suthwanish
  • Carol Dou Xiao Qin
  • Chong Lee Len
  • Claire Wang Kelai
  • Damon Shen
  • Heidi Mo Jinghui
  • Jack Goh Tooan Orng
  • Jieqi Liu
  • John Cheong Ming Chern
  • Jonathan Koh
  • Ken Lee
  • Lester Siew
  • Paula Ruth
  • Sunny Chen
  • Tham Mun Hon
  • Thanawat Thangchadakorn

Regional Morning Meeting Notes: Friday, August 8, 2025

GREATER CHINA Economics Trade: July’s data beats expectations, further near-term strength likely. Sector Automobile: Weekly: YOY PV sales growth remains negative for three straight weeks. Maintain MARKET WEIGHT on the sector. Top BUYs: CATL, Geely and Tuopu. Initiate Coverage Zhejiang Sanhua Intelligent Controls Co (002050 CH/BUY/Rmb27.37/Target: Rmb36.50): Innovative Thermal management leader driving sustainable growth. Initiate coverage with BUY. Target price: Rmb36.50 for A-share, HK$40.00 fo...

Bella Lu Yifei ... (+9)
  • Bella Lu Yifei
  • Carol Dou Xiao Qin
  • Claire Wang Kelai
  • Damon Shen
  • Greater China Research Team
  • Jieqi Liu
  • Ken Lee
  • Sunny Chen
  • Tham Mun Hon

Greater China Daily: Friday, August 8, 2025

Economics Trade July exports grew 7.2% yoy (+1.4ppts), with continued strength in exports to the ASEAN and EU markets. Import growth improved to 4.1% yoy (+3ppt), likely due to a lower base, and support from strong imports of integrated circuits and agricultural products. However, imports of some key commodities saw sharp declines. The Sino-US agreement on another 90-day trade truce may continue to support near-term trade activities. Sector Automobile China’s PV insurance registrations reboun...

Audrey Celia ... (+16)
  • Audrey Celia
  • Bella Lu Yifei
  • Benjaphol Suthwanish
  • Carol Dou Xiao Qin
  • Greater China Research Team
  • Heidi Mo Jinghui
  • Jack Goh Tooan Orng
  • John Cheong Ming Chern
  • Jonathan Koh
  • Julia Pan Mengyao
  • Ken Lee
  • Kong Ho Meng
  • Ming San Soong
  • Sunny Chen
  • Tanapon Cholkadidamrongkul
  • Willinoy Sitorus

Regional Morning Meeting Notes: Thursday, July 31, 2025

GREATER CHINA Sector Healthcare Bi-Weekly: Expecting strong 1H25 results. Maintain OVERWEIGHT. Results Contemporary Amperex Technology (300750 CH/BUY/Rmb277.09 /Target: Rmb390.00) 2Q25: Earnings in line, with margins hitting record-high levels. Maintain A-share at BUY. Downgrade H-share to HOLD. New Oriental Education & Technology Group (EDU US/BUY/US$44.37/Target: US$55.00) ...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Novo - Mounjaro Efficacy Slowing GLP-1 Growth (SELL, TP DKK350, 11pgs)

With US GLP-1 volume growth in diabetes stalling to just 5%, we examine the evidence that Mounjaro’s high efficacy has resulted in a surge of patients getting to HbA1c goal & discontinuing treatment. We analyse the literature & clinical data that shows that GLP-1 market growth could slow dramatically for years to come given Mounjaro is now half the US GLP-1 volume in diabetics. We expect Mounjaro’s NBRx share to be >70% by end 2026, likely resulting in further downgrades to Ozempic consensus. Ba...

Benjaphol Suthwanish ... (+15)
  • Benjaphol Suthwanish
  • Carol Dou Xiao Qin
  • Claire Wang Kelai
  • Damon Shen
  • Desmond Chong Chee Wai
  • Ejann Hiew
  • Jieqi Liu
  • John Cheong Ming Chern
  • Posmarito Pakpahan
  • Shirley Wang Xueyi
  • Stella Guo Yuting
  • Sunny Chen
  • Tham Mun Hon
  • Thanawat Thangchadakorn
  • Wei Xiang Ku

Regional Morning Meeting Notes: Wednesday, July 16, 2025

GREATER CHINA Economics Economic Activity Resilient 1H25 growth of 5.3% yoy belies rising downside pressure. Sector Healthcare Weekly: Gaining strength on robust earnings outlook and pipeline growth. Maintain OVERWEIGHT. Property Property sales and prices weakened further in J...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch